Skip to main content
. 2022 Dec 31;8:505. doi: 10.1038/s41420-022-01289-7

Fig. 2. Combination of ibrutinib and IACS-010759 treatment.

Fig. 2

A Consecutive treatment of REC-1 and MAVER-1 with 3 d ibrutinib pretreatment (400 nM or DMSO), followed by incubation of viable cells with 25 nM IACS-010759 or DMSO and 400 nM ibrutinib or DMSO according to pretreatment for 2 more days, and B Concomitant ibrutinib (400 nM) plus IACS-010759 (25 nM) treatment of REC-1 and MAVER-1 across 4 d; proliferation was assessed by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay and percentages relative to medium control (ctr) pretreated with DMSO (A; N = 3) and relative to medium control (B; N = 4) are shown. C Western blot with PARP, p-BTK, BTK, and β-Actin as loading control (representative for N = 3; see supplementary Original Western Blots), and D Extracellular flux analysis showing oxygen consumption rate vs extracellular acidification rate ratios (N = 4) of 3 d simultaneous treatment with 400 nM ibrutinib and 25 nM IACS-010759. Data are shown as mean ± SEM. Significance was determined by two-sided Student’s t-test or a Welch’s t-test, for equal or unequal variances, respectively. *P < 0.05, **P < 0.01, ***P < 0.001, P > 0.05 not significant (ns). Significance is indicated for relevant comparisons.